Citius Oncology (CTOR) Free Cash Flow (2023 - 2026)

Citius Oncology (CTOR) has reported Free Cash Flow for 4 consecutive years, with -$2.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Free Cash Flow changed N/A year-over-year to -$2.7 million in Q2 2026; TTM through Jun 2026 was -$14.3 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$5.5 million, down 4446.59% from the prior year.
• Free Cash Flow was -$2.7 million for Q2 2026 at Citius Oncology, up from -$3.8 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$100256.0 in Q2 2023 and troughed at -$7.4 million in Q4 2025.
• A 4-year average of -$1.9 million and a median of -$374316.5 in 2023 frame the typical range for Free Cash Flow.
• The widest YoY moves for Free Cash Flow: up 13.56% in 2024, down 265.17% in 2024.
• Over 4 years, Free Cash Flow stood at -$382527.0 in 2023, then advanced by 4.29% to -$366106.0 in 2024, then plunged by 1908.97% to -$7.4 million in 2025, then soared by 63.15% to -$2.7 million in 2026.
• The last three Free Cash Flow figures came in at -$2.7 million (Q2 2026), -$3.8 million (Q1 2026), and -$7.4 million (Q4 2025), per Business Quant data.